Abbott and Bristol-Myers Squibb announced interim results from the Phase 2 portion of a Phase 1b/2 open-label study which showed a high objective response rate (ORR) among patients with relapsed multiple myeloma (MM) who received elotuzumab plus lenalidomide and low-dose dexamethasone. Of 31 previously-treated patients who received elotuzumab 10 mg/kg plus lenalidomide and low-dose dexamethasone, 28 (90%) achieved an objective response. Of 32 previously-treated patients who received elotuzumab 20 mg/kg plus lenalidomide and low-dose dexamethasone, 23 (72%) achieved an objective response. The median time to progression-free survival was not reached after 4.9 months of follow-up.

Elotuzumab is a humanized monoclonal antibody which is being developed to treat relapsed multiple myeloma.

For more information call (800) 321-1335 or visit www.bms.com or www.abbott.com.